Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07634471 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 960
- Enrollment target
NCT07634471: Recruiting Phase 2 study, sponsored by Merck Sharp & Dohme.
NCT07634471 is a Phase 2 study that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 960 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (622% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07634471, a Phase 2 study, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 960 participants
- Enrollment target
Study Summary
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)
Primary Outcome
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL Rituximab
- DRUG Bendamustine
- BIOLOGICAL MK-1045
- BIOLOGICAL Rituximab biosimilar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 960 participants |
| Start Date | 2026-06-22 |
| Est. Completion | 2035-07-23 |
| Phase | Phase 2 |
What NCT07634471 shows while recruiting
NCT07634471 is an interventional study that assigns participants to a tested intervention. The registered 960 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (622% higher).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT07634471 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07634471 about?
NCT07634471 is a clinical study titled "A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)". Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type ...
What is the current status of trial NCT07634471?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 960 participants. The study started on 2026-06-22. Estimated completion is 2035-07-23.
What interventions are being tested in trial NCT07634471?
The interventions under investigation include: Cyclophosphamide (DRUG), Rituximab (BIOLOGICAL), Bendamustine (DRUG), MK-1045 (BIOLOGICAL), Rituximab biosimilar (BIOLOGICAL).
Who is sponsoring clinical trial NCT07634471?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07634471's enrollment target sits among peer trials
960 28th of 2000 higher than 1,972 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
- NCT05178498 · 960 participants
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
- NCT05946629 · 960 participants · NA
SELUTION 4 De Novo Small Vessel IDE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI